Dow Jones Newswires: Takeda trial for Crohn’s Perianal Fistulas treatment misses primary endpoint

Takeda said Tuesday its trial of darvadstrocel in the treatment of complex Crohn’s Perianal Fistulas didn’t meet its primary endpoint based on topline data.

Previous post : Elon Musk’s X to start charging new, unverified users in test program in two countries
Next post Dow Jones Newswires: China’s BYD forecasts higher third-quarter profit on record EV sales